1/ GLP-1 Users Who Are Weight Training The conversation changes when GLP-1 drugs enter the picture. Semaglutide. Tirzepatide. Retatrutide. These drugs help people eat less. That’s the point. But rapid weight loss can include loss of: • Fat • Muscle Preserving muscle becomes one of the most important goals of treatment. Protein and resistance training become strategic tools—not optional extras.

3/ The real objective of GLP-1 therapy is not merely becoming lighter. It’s improving body composition. The ideal outcome: Less fat. More preserved muscle. Better metabolic health. Resistance training plus adequate protein appears to be the most evidence-supported strategy currently available. Important caveat: Patients with chronic kidney disease, advanced renal impairment, or other significant medical conditions require individualized medical guidance before increasing protein intake. One size does not fit all.

1/ Adults Who Weight Train Once resistance training enters the picture, protein requirements change. The best available evidence suggests muscle-building benefits rise with increasing protein intake up to roughly: 1.6 g/kg/day Beyond that point, gains tend to plateau for most individuals. More protein is not always more muscle. This finding comes from one of the most influential meta-analyses in sports nutrition. The evidence points toward a sweet spot—not an endless upward curve.

3/ Athletes pursuing maximal performance sometimes consume: 1.8–2.2 g/kg/day But evidence suggests most recreational lifters achieve nearly all available benefit closer to: 1.6 g/kg/day More isn’t necessarily harmful for healthy kidneys. It may simply provide diminishing returns. Exceptions: • Elite athletes • Calorie restriction • Contest preparation • Certain endurance sports The goal should be evidence-based adequacy—not social media excess.

1/ Healthy Adults Seeking Healthy Aging The protein RDA (0.8 g/kg/day) is one of the most misunderstood numbers in nutrition. It was designed to prevent deficiency—not optimize health, muscle retention, strength, or healthy aging. For a 70 kg (154 lb) adult: • RDA = 56 g/day That may be enough to avoid deficiency. It is not necessarily enough to maintain muscle mass over decades. As we age, skeletal muscle becomes one of our most important metabolic organs—supporting glucose disposal, mobility, balance, independence, and resilience. The question is not: “What’s the least protein I can survive on?” The question is: “What amount best supports healthy aging?” Current evidence suggests those are very different numbers.

3/ Protein quality matters. Protein timing probably matters. Resistance exercise matters. But for most healthy adults, the biggest mistake is simply under-consuming protein earlier in the day. A practical approach: • Protein at breakfast • Protein at lunch • Protein at dinner Rather than consuming nearly everything at night. Caveat: Individuals with chronic kidney disease should not automatically increase protein intake without medical supervision. Healthy kidneys and diseased kidneys are not the same situation. Personalization matters.

USA 3:0 Paraguay Halftime

One of the most interesting emerging ideas in post-infectious illness research is that many different infections may trigger similar downstream biological disturbances, producing remarkably similar symptom patterns despite very different initial pathogens. This is still a hypothesis—not a settled fact—but the evidence supporting biological convergence continues to grow. SARS-CoV-2. Epstein-Barr virus. Influenza. Q Fever. West Nile Virus. Ross River Virus. Various bacterial infections. Different pathogens. Different tissues. Different immune responses. Yet many patients develop a strikingly similar syndrome characterized by: • Fatigue • Post-exertional malaise (PEM) • Cognitive dysfunction (“brain fog”) • Dysautonomia/POTS • Exercise intolerance • Sleep disturbances • Sensory symptoms What if the pathogen is not the whole story? Several recent reviews suggest that diverse infectious triggers may converge upon a limited number of vulnerable physiological systems. Among the repeatedly identified candidates: 🔹 Mitochondrial dysfunction and impaired ATP production 🔹 Endothelial and microvascular dysfunction 🔹 Autonomic nervous system dysregulation 🔹 Neuroinflammation and glial activation 🔹 Persistent immune activation 🔹 Altered cellular stress-response pathways Komaroff and colleagues have argued that Long COVID, ME/CFS, and other post-acute infection syndromes share many of these abnormalities, including mitochondrial dysfunction, endothelial dysfunction, immune dysregulation, and autonomic disturbances. (PubMed) The mitochondrial story is particularly intriguing. Independent reviews in both Long COVID and ME/CFS describe evidence for impaired oxidative phosphorylation, reduced ATP generation, altered metabolic flexibility, oxidative stress, and abnormalities in cellular energy production. (PMC) This matters because virtually every symptom reported by patients—fatigue, exercise intolerance, cognitive dysfunction, autonomic instability—depends heavily on adequate energy availability at the cellular level. The autonomic nervous system may represent another point of convergence. Multiple studies have documented orthostatic intolerance, POTS-like syndromes, altered sympathetic/parasympathetic balance, and broader autonomic dysfunction in both Long COVID and ME/CFS. (Taylor & Francis Online) Then there is post-exertional malaise (PEM)—arguably the most distinctive symptom shared by many patients. Rather than simple deconditioning, emerging evidence suggests PEM may involve a complex interaction among mitochondrial dysfunction, immune activation, neuroinflammation, autonomic dysregulation, vascular abnormalities, and skeletal muscle pathology. (PMC) This convergence model helps explain an observation clinicians have made for decades: Patients often arrive through different doors—but end up in remarkably similar rooms. An EBV-triggered illness may not be biologically identical to Long COVID. An influenza-triggered syndrome may not be identical to ME/CFS. But they may share enough downstream physiological disturbances that the resulting symptom patterns overlap substantially. Importantly, none of this means we have found a single cause. The current evidence points toward a network of interacting mechanisms rather than one master explanation. Different patients may arrive at similar symptoms through different combinations of mitochondrial dysfunction, endothelial injury, immune dysregulation, autonomic dysfunction, neuroinflammation, and metabolic abnormalities. The future of research may therefore be less about identifying “the pathogen” and more about understanding why different insults appear capable of converging on the same vulnerable biological systems. If that hypothesis proves correct, it could reshape how we classify—and eventually treat—Long COVID, ME/CFS, and other post-infectious syndromes.